Novartis news

Sandoz receives approval for first-ever Japanese biosimilar

Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months

New biological therapy Ilaris® approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease

Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine

Afinitor® Phase II data show positive results for patients with multiple types of lymphoma, leading to Phase III trial

Tasigna® shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia

Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust

One-year Phase III study confirms Ilaris® offers long-term remission in patients with CAPS, a severe lifelong auto-inflammatory disease

Novartis successfully launches EUR 1.5 billion notes issue

FDA approves Reclast® to prevent osteoporosis in postmenopausal women with convenient less frequent dosing

Syndicate content